Toxicity and dose-response studies of 1,25-(OH)2-16-ene-23-yne vitamin D3 in transgenic mice

Craig L. Wilkerson, Soesiawati R. Darjatmoko, Mary J. Lindstrom, Daniel Albert

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The vitamin D3 analogue 1,25-(OH)2-16-ene-23-yne vitamin D3 (16,23- D3) in doses with low systemic toxicity has been demonstrated to inhibit retinoblastoma growth in transgenic mice. This study examines the dose- dependent response for inhibition of tumor growth in transgenic mice with retinoblastoma and evaluates the in vivo toxicity of 16,23-D3 in nontransgenic mice. Transgenic 8-10-week-old mice with retinoblastoma (n = 119) were randomly assigned to groups receiving 1.0, 0.75, 0.5, 0.35, 0.2, or 0.05 μg of 16,23-D3 and a vehicle alone (control) group i.p. five times a week for 5 weeks. An additional control group received no injection. Eyes were enucleated one week after the end of treatment, and tumor areas were measured. To determine the toxic dose, transgene-negative littermates received 0.5, 1.0, 1.5, 2.5, 3.5, 4.5, or 5.0 μg of 16,23-D3, and control groups received vehicle alone, 5 days a week for 5 weeks. Serum calcium levels were measured, and necropsies were performed on animals from each group. In the dose-response study, tumor growth inhibition was greatest in the group receiving 0.35 μg (55% inhibition; P = 0.0056) and was also significant in the group receiving 0.5 μg (42% inhibition; P = 0.036). The systemic toxic effects due to hypercalcemia occurred at doses of ≤1.0 μg. 16,23-D3 inhibits tumor growth at doses ≤0.35 μg and shows toxic effects at doses ≤1.0 μg related to hypercalcemia in mice fed an unrestricted diet. No toxicity was observed with lower doses.

Original languageEnglish (US)
Pages (from-to)2253-2256
Number of pages4
JournalClinical Cancer Research
Volume4
Issue number9
StatePublished - Sep 1 1998
Externally publishedYes

Fingerprint

Cholecalciferol
Transgenic Mice
Retinoblastoma
Poisons
Hypercalcemia
Growth
Control Groups
Neoplasms
Transgenes
Diet
Calcium
Injections
Serum
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Toxicity and dose-response studies of 1,25-(OH)2-16-ene-23-yne vitamin D3 in transgenic mice. / Wilkerson, Craig L.; Darjatmoko, Soesiawati R.; Lindstrom, Mary J.; Albert, Daniel.

In: Clinical Cancer Research, Vol. 4, No. 9, 01.09.1998, p. 2253-2256.

Research output: Contribution to journalArticle

Wilkerson, CL, Darjatmoko, SR, Lindstrom, MJ & Albert, D 1998, 'Toxicity and dose-response studies of 1,25-(OH)2-16-ene-23-yne vitamin D3 in transgenic mice', Clinical Cancer Research, vol. 4, no. 9, pp. 2253-2256.
Wilkerson, Craig L. ; Darjatmoko, Soesiawati R. ; Lindstrom, Mary J. ; Albert, Daniel. / Toxicity and dose-response studies of 1,25-(OH)2-16-ene-23-yne vitamin D3 in transgenic mice. In: Clinical Cancer Research. 1998 ; Vol. 4, No. 9. pp. 2253-2256.
@article{4095202ba6314a059b7276de9d9c9925,
title = "Toxicity and dose-response studies of 1,25-(OH)2-16-ene-23-yne vitamin D3 in transgenic mice",
abstract = "The vitamin D3 analogue 1,25-(OH)2-16-ene-23-yne vitamin D3 (16,23- D3) in doses with low systemic toxicity has been demonstrated to inhibit retinoblastoma growth in transgenic mice. This study examines the dose- dependent response for inhibition of tumor growth in transgenic mice with retinoblastoma and evaluates the in vivo toxicity of 16,23-D3 in nontransgenic mice. Transgenic 8-10-week-old mice with retinoblastoma (n = 119) were randomly assigned to groups receiving 1.0, 0.75, 0.5, 0.35, 0.2, or 0.05 μg of 16,23-D3 and a vehicle alone (control) group i.p. five times a week for 5 weeks. An additional control group received no injection. Eyes were enucleated one week after the end of treatment, and tumor areas were measured. To determine the toxic dose, transgene-negative littermates received 0.5, 1.0, 1.5, 2.5, 3.5, 4.5, or 5.0 μg of 16,23-D3, and control groups received vehicle alone, 5 days a week for 5 weeks. Serum calcium levels were measured, and necropsies were performed on animals from each group. In the dose-response study, tumor growth inhibition was greatest in the group receiving 0.35 μg (55{\%} inhibition; P = 0.0056) and was also significant in the group receiving 0.5 μg (42{\%} inhibition; P = 0.036). The systemic toxic effects due to hypercalcemia occurred at doses of ≤1.0 μg. 16,23-D3 inhibits tumor growth at doses ≤0.35 μg and shows toxic effects at doses ≤1.0 μg related to hypercalcemia in mice fed an unrestricted diet. No toxicity was observed with lower doses.",
author = "Wilkerson, {Craig L.} and Darjatmoko, {Soesiawati R.} and Lindstrom, {Mary J.} and Daniel Albert",
year = "1998",
month = "9",
day = "1",
language = "English (US)",
volume = "4",
pages = "2253--2256",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Toxicity and dose-response studies of 1,25-(OH)2-16-ene-23-yne vitamin D3 in transgenic mice

AU - Wilkerson, Craig L.

AU - Darjatmoko, Soesiawati R.

AU - Lindstrom, Mary J.

AU - Albert, Daniel

PY - 1998/9/1

Y1 - 1998/9/1

N2 - The vitamin D3 analogue 1,25-(OH)2-16-ene-23-yne vitamin D3 (16,23- D3) in doses with low systemic toxicity has been demonstrated to inhibit retinoblastoma growth in transgenic mice. This study examines the dose- dependent response for inhibition of tumor growth in transgenic mice with retinoblastoma and evaluates the in vivo toxicity of 16,23-D3 in nontransgenic mice. Transgenic 8-10-week-old mice with retinoblastoma (n = 119) were randomly assigned to groups receiving 1.0, 0.75, 0.5, 0.35, 0.2, or 0.05 μg of 16,23-D3 and a vehicle alone (control) group i.p. five times a week for 5 weeks. An additional control group received no injection. Eyes were enucleated one week after the end of treatment, and tumor areas were measured. To determine the toxic dose, transgene-negative littermates received 0.5, 1.0, 1.5, 2.5, 3.5, 4.5, or 5.0 μg of 16,23-D3, and control groups received vehicle alone, 5 days a week for 5 weeks. Serum calcium levels were measured, and necropsies were performed on animals from each group. In the dose-response study, tumor growth inhibition was greatest in the group receiving 0.35 μg (55% inhibition; P = 0.0056) and was also significant in the group receiving 0.5 μg (42% inhibition; P = 0.036). The systemic toxic effects due to hypercalcemia occurred at doses of ≤1.0 μg. 16,23-D3 inhibits tumor growth at doses ≤0.35 μg and shows toxic effects at doses ≤1.0 μg related to hypercalcemia in mice fed an unrestricted diet. No toxicity was observed with lower doses.

AB - The vitamin D3 analogue 1,25-(OH)2-16-ene-23-yne vitamin D3 (16,23- D3) in doses with low systemic toxicity has been demonstrated to inhibit retinoblastoma growth in transgenic mice. This study examines the dose- dependent response for inhibition of tumor growth in transgenic mice with retinoblastoma and evaluates the in vivo toxicity of 16,23-D3 in nontransgenic mice. Transgenic 8-10-week-old mice with retinoblastoma (n = 119) were randomly assigned to groups receiving 1.0, 0.75, 0.5, 0.35, 0.2, or 0.05 μg of 16,23-D3 and a vehicle alone (control) group i.p. five times a week for 5 weeks. An additional control group received no injection. Eyes were enucleated one week after the end of treatment, and tumor areas were measured. To determine the toxic dose, transgene-negative littermates received 0.5, 1.0, 1.5, 2.5, 3.5, 4.5, or 5.0 μg of 16,23-D3, and control groups received vehicle alone, 5 days a week for 5 weeks. Serum calcium levels were measured, and necropsies were performed on animals from each group. In the dose-response study, tumor growth inhibition was greatest in the group receiving 0.35 μg (55% inhibition; P = 0.0056) and was also significant in the group receiving 0.5 μg (42% inhibition; P = 0.036). The systemic toxic effects due to hypercalcemia occurred at doses of ≤1.0 μg. 16,23-D3 inhibits tumor growth at doses ≤0.35 μg and shows toxic effects at doses ≤1.0 μg related to hypercalcemia in mice fed an unrestricted diet. No toxicity was observed with lower doses.

UR - http://www.scopus.com/inward/record.url?scp=0031716628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031716628&partnerID=8YFLogxK

M3 - Article

C2 - 9748146

AN - SCOPUS:0031716628

VL - 4

SP - 2253

EP - 2256

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -